Cognitive impairment and dementia in young onset Parkinson's disease.

Male Humans Middle Aged Female Parkinson Disease / complications Cognitive Dysfunction / epidemiology Cognition Sleep Dementia / epidemiology Neuropsychological Tests

Dementia Mild cognitive impairment Parkinson's disease Young onset Parkinson’s disease

Journal

Journal of neurology

ISSN: 1432-1459

Titre abrégé: J Neurol

Pays: Germany

ID NLM: 0423161

Informations de publication

Date de publication:
Dec 2023

Historique:

received: 28 06 2023

accepted: 31 07 2023

revised: 30 07 2023

medline: 9 11 2023

pubmed: 14 8 2023

entrez: 14 8 2023

Statut: ppublish

Résumé

Patients with young-onset Parkinson's disease (YOPD) have a slower progression. Our aim was to analyze the change in cognitive function in YOPD compared to patients with a later onset and controls. Patients with Parkinson's disease (PD) and controls from the COPPADIS cohort were included. Cognitive function was assessed with the Parkinson's Disease Cognitive Rating Scale (PD-CRS) at baseline (V0), 2-year ± 1 month (V2y), and 4-year ± 3 months follow-up (V4y). Regarding age from symptoms onset, patients were classified as YOPD (< 50 years) or non-YOPD (≥ 50). A score in the PD-CRS < 81 was defined as cognitive impairment (CI): ≤ 64 dementia; 65-80 mild cognitive impairment (MCI). One-hundred and twenty-four YOPD (50.7 ± 7.9 years; 66.1% males), 234 non-YOPD (67.8 ± 7.8 years; 59.3% males) patients, and 205 controls (61 ± 8.3 years; 49.5% males) were included. The score on the PD-CRS and its subscore domains was higher at all visits in YOPD compared to non-YOPD patients and to controls (p < 0.0001 in all analysis), but no differences were detected between YOPD patients and controls. Only non-YOPD patients had significant impairment in their cognitive function from V0 to V4y (p < 0.0001). At V4y, the frequency of dementia and MCI was 5% and 10% in YOPD compared to 25.2% and 22.3% in non-YOPD patients (p < 0.0001). A lower score on the Parkinson's Disease Sleep Scale at baseline was a predictor of CI at V4y in YOPD patients (Adjusted R Cognitive dysfunction progressed more slowly in YOPD than in non-YOPD patients.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE

Patients with young-onset Parkinson's disease (YOPD) have a slower progression. Our aim was to analyze the change in cognitive function in YOPD compared to patients with a later onset and controls.

PATIENTS AND METHODS METHODS

Patients with Parkinson's disease (PD) and controls from the COPPADIS cohort were included. Cognitive function was assessed with the Parkinson's Disease Cognitive Rating Scale (PD-CRS) at baseline (V0), 2-year ± 1 month (V2y), and 4-year ± 3 months follow-up (V4y). Regarding age from symptoms onset, patients were classified as YOPD (< 50 years) or non-YOPD (≥ 50). A score in the PD-CRS < 81 was defined as cognitive impairment (CI): ≤ 64 dementia; 65-80 mild cognitive impairment (MCI).

RESULTS RESULTS

One-hundred and twenty-four YOPD (50.7 ± 7.9 years; 66.1% males), 234 non-YOPD (67.8 ± 7.8 years; 59.3% males) patients, and 205 controls (61 ± 8.3 years; 49.5% males) were included. The score on the PD-CRS and its subscore domains was higher at all visits in YOPD compared to non-YOPD patients and to controls (p < 0.0001 in all analysis), but no differences were detected between YOPD patients and controls. Only non-YOPD patients had significant impairment in their cognitive function from V0 to V4y (p < 0.0001). At V4y, the frequency of dementia and MCI was 5% and 10% in YOPD compared to 25.2% and 22.3% in non-YOPD patients (p < 0.0001). A lower score on the Parkinson's Disease Sleep Scale at baseline was a predictor of CI at V4y in YOPD patients (Adjusted R

CONCLUSION CONCLUSIONS

Cognitive dysfunction progressed more slowly in YOPD than in non-YOPD patients.

Identifiants

DOI: 10.1007/s00415-023-11921-w PMID: 37578489

pubmed: 37578489

doi: 10.1007/s00415-023-11921-w

pii: 10.1007/s00415-023-11921-w

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

5793-5812

Investigateurs

A D Adarmes (AD)

M Almeria (M)

M G Alonso Losada (MGA)

A Alonso Cánovas (AA)

F Alonso Frech (FA)

R Alonso Redondo (RA)

I Álvarez (I)

M Álvarez Sauco (MÁ)

A Aneiros Díaz (AA)

S Arnáiz (S)

S Arribas (S)

A Ascunce Vidondo (AA)

M Aguilar (M)

M A Ávila (MA)

N Nernardo Lambrich (NN)

H Bejr-Kasem (H)

M Blázquez Estrada (MB)

M Botí (M)

C Borrue (C)

M T Buongiorno (MT)

C Cabello González (CC)

I Cabo López (IC)

N Caballol (N)

A Cámara Lorenzo (AC)

H Canfield Medina (HC)

E Carabajal Pendón (EC)

F Carrillo (F)

F J Carrillo Padilla (FJC)

E Casas (E)

M J Catalán (MJ)

P Clavero (P)

A Cortina Fernández (AC)

M Cosgaya (M)

A Cots Foraster (AC)

A Crespo Cuevas (AC)

E Cubo (E)

T de Deus Fonticoba (T)

O de Fábregues-Boixar (O)

M Díez-Fairen (M)

J Dotor García-Soto (JD)

E Erro (E)

S Escalante (S)

EEstelrich Peyret (E)

N Fernández Guillán (NF)

P Gámez (P)

M Gallego (M)

J García Caldentey (JG)

C García Campos (CG)

C García Díez (CG)

J M García Moreno (JMG)

I Gastón (I)

M P Gómez Garre (MPG)

V Gómez Mayordomo (VG)

J González Aloy (JG)

I González-Aramburu (I)

J González Ardura (JG)

B González García (BG)

M J González Palmás (MJG)

G R González Toledo (GRG)

A Golpe Díaz (AG)

M Grau Solá (MG)

G Guardia (G)

J Hernández Vara (JH)

A Horta-Barba (A)

DIdoate Calderón (D)

J Infante (J)

S Jesús (S)

J Kulisevsky (J)

M Kurtis (M)

C Labandeira (C)

M A Labrador (MA)

F Lacruz (F)

M Lage Castro (ML)

S Lastres Gómez (SL)

I Legarda (I)

NLópez Ariztegui (N)

L M López Díaz (LML)

D López Domínguez (DL)

L López Manzanares (LL)

B López Seoane (BL)

S Lucas Del Pozo (SL)

Y Macías (Y)

M Mata (M)

G Martí Andres (GM)

M J Martí (MJ)

J C Martínez Castrillo (JCM)

P Martinez-Martin (P)

D McAfee (D)

M T Meitín (MT)

Z Mendoza Plasencia (ZM)

M Menéndez González (MM)

C Méndez Del Barrio (CM)

P Mir (P)

J Miranda Santiago (JM)

M I Morales Casado (MIM)

A Moreno Diéguez (AM)

I Muro García (IM)

V Nogueira (V)

A Novo Amado (AN)

S Novo Ponte (SN)

C Ordás (C)

J Pagonabarraga (J)

I Pareés (I)

B Pascual-Sedano (B)

P Pastor (P)

A Pérez Fuertes (AP)

R Pérez Noguera (RP)

A Planas-Ballvé (A)

L Planellas (L)

M A Prats (MA)

C Prieto Jurczynska (CP)

V Puente (V)

M Pueyo Morlans (MP)

A Puig Daví (AP)

N Redondo Rafales (NR)

L Rodríguez Méndez (LR)

ABRodríguez Pérez (A)

F Roldán (F)

M Ruíz De Arcos (MR)

J Ruíz Martínez (JR)

P Sánchez Alonso (PS)

M Sánchez-Carpintero (M)

G Sánchez Díez (GS)

A Sánchez Rodríguez (AS)

P Santacruz (P)

D Santos García (DS)

J C Segundo Rodríguez (JCS)

M Seijo (M)

M Sierra Peña (MS)

B Solano Vila (BS)

E Suárez Castro (ES)

J P Tartari (JP)

C Valero (C)

L Vargas (L)

L Vela (L)

C Villanueva (C)

Informations de copyright

Références

Greenland JC, Williams-Gray CH, Barker RA (2019) The clinical heterogeneity of Parkinson’s disease and its therapeutic implications. Eur J Neurosci 49:328–338

pubmed: 30059179 doi: 10.1111/ejn.14094

Titova N, Padmakumar C, Lewis SJG, Chaudhuri KR (2017) Parkinson’s: a syndrome rather than a disease? J Neural Transm (Vienna) 124:907–914

pubmed: 28028643 doi: 10.1007/s00702-016-1667-6

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184

pubmed: 1564476 pmcid: 1014720 doi: 10.1136/jnnp.55.3.181

Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601

pubmed: 26474316 doi: 10.1002/mds.26424

Post B, van den Heuvel L, van Prooije T, van Ruissen X, van de Warrenburg B, Nonnekes J (2020) Young onset Parkinson’s disease: a modern and tailored approach. J Parkinsons Dis 10(s1):S29-36

pubmed: 32651336 pmcid: 7592661 doi: 10.3233/JPD-202135

Morales-Briceno H, Mohammad SS, Post B et al (2020) Clinical and neuroimaging phenotypes of genetic parkinsonism from infancy to adolescence. Brain 143:751–770

pubmed: 31800013 doi: 10.1093/brain/awz345

Mehanna R, Jankovic J (2019) Young-onset Parkinson’s disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord 65:39–48

pubmed: 31176633 doi: 10.1016/j.parkreldis.2019.06.001

Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG (1993) Environmental antecedents of young-onset Parkinson’s disease. Neurology 43:1150–1158

pubmed: 8170560 doi: 10.1212/WNL.43.6.1150

Pagano G, Ferrara N, Brooks DJ, Pavese N (2016) Age at onset and Parkinson disease phenotype. Neurology 86:1400–1407

pubmed: 26865518 pmcid: 4831034 doi: 10.1212/WNL.0000000000002461

Schrag A, Hovris A, Morley D, Quinn N, Jahanshahim M (2003) Young- versus older-onset Parkinson’s disease: impact of disease and psychosocial consequences. Mov Disord 18:1250–1256

pubmed: 14639664 doi: 10.1002/mds.10527

Klepac N, Habek M, Adamec I et al (2013) An update on the management of young-onset Parkinson’s disease. Degener Neurol Neuromuscul Dis 2:53–62

pubmed: 30890879 pmcid: 6065598

Quinn N, Critchley P, Marsden CD (1987) Young onset Parkinson’s disease. Mov Disord 2:73–91

pubmed: 3504266 doi: 10.1002/mds.870020201

Holden HM, Schweer CN, Tröster AI (2021) Impact of mild cognitive impairment on quality of life in young and typical onset Parkinson’s disease. Mov Disord Clin Pract 9:69–75

pubmed: 35005067 pmcid: 8721826 doi: 10.1002/mdc3.13353

Willis AW, Schootman M, Kung N, Racette BA (2013) Epidemiology and neuropsychiatric manifestations of young onset Parkinson’s disease in the United States. Parkinsonism Relat Disord 19:202–206

pubmed: 23083512 doi: 10.1016/j.parkreldis.2012.09.014

Santos García D, Jesús S, Aguilar M et al (2019) COPPADIS Study Group. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015): an ongoing global Parkinson’s disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation. Eur J Neurol 26:1399–1407

pubmed: 31179586 doi: 10.1111/ene.14008

Santos-García D, Mir P, Cubo E et al (2016) COPPADIS Study Group. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multi-center, non-interventional, long-term study on Parkinson’s disease progression. BMC Neurol 16:26

pubmed: 26911448 pmcid: 4766717 doi: 10.1186/s12883-016-0548-9

Zhou Z, Zhou X, Xiang Y et al (2022) Subtyping of early-onset Parkinson’s disease using cluster analysis: a large cohort study. Front Aging Neurosci 14:1040293

pubmed: 36437996 pmcid: 9692000 doi: 10.3389/fnagi.2022.1040293

Zhao Y, Qin L, Pan H et al (2020) The role of genetics in Parkinson’s disease: a large cohort study in Chinese mainland population. Brain 143:2220–2234

pubmed: 32613234 doi: 10.1093/brain/awaa167

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 23(3):17013

doi: 10.1038/nrdp.2017.13

Pagonabarraga J, Kulisevsky J, Llebaria G, García-Sánchez C, Pascual-Sedano B, Gironell A (2008) Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. Mov Disord 23:998–1005

pubmed: 18381647 doi: 10.1002/mds.22007

Fernandez de Bobadilla R, Pagonabarraga J, Martinez-Horta S, Pascual-Sedano B, Campolongo A, Kulisevsky J (2013) Parkinson’s disease-cognitive rating scale: psychometrics for mild cognitive impairment. Mov Disord 28:1376–1383

pubmed: 23873810 doi: 10.1002/mds.25568

Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: an updated proposal including Opicapone and Safinamide. Mov Disord Clin Pract 7:343–345

pubmed: 32258239 pmcid: 7111582 doi: 10.1002/mdc3.12921

Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson’s disease. Brain 132(Pt 11):2947–2957

pubmed: 19759203 doi: 10.1093/brain/awp234

Ferguson LW, Rajput AH, Rajput A (2016) Early-onset vs. late-onset Parkinson’s disease: a clinical-pathological study. Can J Neurol Sci 43:113–119

pubmed: 26189779 doi: 10.1017/cjn.2015.244

Schrag A, Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 5:355–363

pubmed: 16545752 doi: 10.1016/S1474-4422(06)70411-2

Wickremaratchi MM, Ben-Shlomo Y, Morris HR (2009) The effect of onset age on the clinical features of Parkinson’s disease. Eur J Neurol 16:450–456

pubmed: 19187262 doi: 10.1111/j.1468-1331.2008.02514.x

Lawson RA, Yarnall AJ, Duncan GW et al (2014) Severity of mild cognitive impairment in early Parkinson’s disease contributes to poorer quality of life. Parkinsonism Relat Disord 20:1071–1075

pubmed: 25074728 pmcid: 4194347 doi: 10.1016/j.parkreldis.2014.07.004

Tang H, Huang J, Nie K et al (2016) Cognitive profile of Parkinson’s disease patients: a comparative study between early-onset and late-onset Parkinson’s disease. Int J Neurosci 126:227–234

pubmed: 26001202 doi: 10.3109/00207454.2015.1010646

Mayeux R, Denaro J, Hemenegildo N et al (1992) A population-based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch Neurol 49:492–497

pubmed: 1580811 doi: 10.1001/archneur.1992.00530290076015

Anang JB, Gagnon JF, Bertrand JA et al (2014) Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 83:1253–1260

pubmed: 25171928 pmcid: 4180482 doi: 10.1212/WNL.0000000000000842

Phongpreecha T, Cholerton B, Mata IF et al (2020) Multivariate prediction of dementia in Parkinson’s disease. NPJ Parkinsons Dis 6:20

pubmed: 32885039 pmcid: 7447766 doi: 10.1038/s41531-020-00121-2

Bohnen NI, Hu MTM (2019) Sleep disturbance as potential risk and progression factor for Parkinson’s disease. J Parkinsons Dis 9:603–614

pubmed: 31227656 pmcid: 6700634 doi: 10.3233/JPD-191627

Matsumoto S, Tsunematsu T (2021) Association between Sleep, Alzheimer’s, and Parkinson’s disease. Biology (Basel) 10:1127

pubmed: 34827122

Minakawa EN (2022) Bidirectional relationship between sleep disturbances and Parkinson’s disease. Front Neurol 13:927994

pubmed: 35923835 pmcid: 9342689 doi: 10.3389/fneur.2022.927994

Leocadi M, Canu E, Donzuso G et al (2022) Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinson’s disease patients. J Neurol 269:1485–1500

pubmed: 34297177 doi: 10.1007/s00415-021-10713-4

Santos García D, de Deus Fonticoba T, Suárez Castro E et al (2019) Coppadis Study Group. Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson’s disease patients: results from the COPPADIS Study Cohort. Parkinsonism Relat Disord 66:151–157

pubmed: 31409572 doi: 10.1016/j.parkreldis.2019.07.031

Spica V, Pekmezović T, Svetel M, Kostić VS (2013) Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson’s disease. J Neurol 260:131–137

pubmed: 22820720 doi: 10.1007/s00415-012-6600-9

Kim R, Shin JH, Park S, Kim HJ, Jeon B (2020) Longitudinal evolution of non-motor symptoms according to age at onset in early Parkinson’s disease. J Neurol Sci 418:117157

pubmed: 33039976 doi: 10.1016/j.jns.2020.117157

Vela L, Martínez Castrillo JC, García Ruiz P et al (2016) The high prevalence of impulse control behaviors in patients with early-onset Parkinson’s disease: a cross-sectional multi-center study. J Neurol Sci 368:150–154

pubmed: 27538621 doi: 10.1016/j.jns.2016.07.003

Kelly MJ, Lawton MA, Baig F et al (2019) Predictors of motor complications in early Parkinson’s disease: a prospective cohort study. Mov Disord 34:1174–1183

pubmed: 31283854 pmcid: 6771533 doi: 10.1002/mds.27783

Te Groen M, Bloem BR, Wu SS, Post B (2021) Parkinson’s Foundation Quality Improvement Initiative investigators. Better quality of life and less caregiver strain in young-onset Parkinson’s disease: a multicentre retrospective cohort study. J Neurol 268:1102–1109

doi: 10.1007/s00415-020-10266-y

Knipe MD, Wickremaratchi MM, Wyatt-Haines E, Morris HR, Ben-Shlomo Y (2011) Quality of life in young- compared with late-onset Parkinson’s disease. Mov Disord 26:2011–2018

pubmed: 21574185 doi: 10.1002/mds.23763

Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15:1112–1118

pubmed: 11104193 doi: 10.1002/1531-8257(200011)15:6<1112::AID-MDS1008>3.0.CO;2-A

Lawton M, Ben-Shlomo Y, May MT et al (2018) Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression. J Neurol Neurosurg Psychiatry 89:1279–1287

pubmed: 30464029 doi: 10.1136/jnnp-2018-318337

Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB (2015) New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 72:863–873

pubmed: 26076039 doi: 10.1001/jamaneurol.2015.0703

Dubois B, Burn D, Goetz C et al (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324

pubmed: 18098298 doi: 10.1002/mds.21844